SARS-CoV-2 infection and persistence in the human body and brain at autopsy
Abstract Coronavirus disease 2019 (COVID-19) is known to cause multi-organ dysfunction,–
during acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
during acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?
WS Ho, R Zhang, YL Tan, CLL Chai - Pharmacological Research, 2022 - Elsevier
Abstract The coronavirus disease 2019 (COVID-19) pandemic had grounded the world to a
standstill. As the disease continues to rage two years on, it is apparent that effective …
standstill. As the disease continues to rage two years on, it is apparent that effective …
[HTML][HTML] A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters
TL Bricker, TL Darling, AO Hassan, HH Harastani… - Cell reports, 2021 - cell.com
The development of an effective vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the etiologic agent of coronavirus disease 2019 (COVID-19) …
coronavirus 2 (SARS-CoV-2), the etiologic agent of coronavirus disease 2019 (COVID-19) …
[HTML][HTML] Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model
K Rosenke, A Okumura, MC Lewis, F Feldmann… - JCI insight, 2022 - ncbi.nlm.nih.gov
The recent emergence of the SARS-CoV-2 Omicron variant of concern (VOC), which
contains a heavily mutated spike protein capable of escaping preexisting immunity …
contains a heavily mutated spike protein capable of escaping preexisting immunity …
Hydroxychloroquine for COVID19: the curtains close on a comedy of errors
Early in the COVID-19 pandemic, there was a desperate need for a therapy against the
scourge which was decimating health care systems worldwide. As systems became …
scourge which was decimating health care systems worldwide. As systems became …
COVID-19 drug discovery and treatment options
Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused substantial morbidity and …
respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused substantial morbidity and …
SARS-CoV-2 immunity in animal models
Z Chen, Y Yuan, Q Hu, A Zhu, F Chen, S Li… - Cellular & molecular …, 2024 - nature.com
The COVID-19 pandemic, which was caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), has become a worldwide health crisis due to its …
coronavirus 2 (SARS-CoV-2), has become a worldwide health crisis due to its …
Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial
I Schwartz, ME Boesen, G Cerchiaro… - … Open Access Journal, 2021 - cmajopen.ca
Background: Identification of therapies to prevent severe COVID-19 remains a priority. We
sought to determine whether hydroxychloroquine treatment for outpatients with SARS-CoV-2 …
sought to determine whether hydroxychloroquine treatment for outpatients with SARS-CoV-2 …
Co-Administration of favipiravir and the remdesivir metabolite GS-441524 effectively reduces SARS-CoV-2 replication in the lungs of the Syrian hamster model
S Chiba, M Kiso, N Nakajima, S Iida, T Maemura… - Mbio, 2022 - Am Soc Microbiol
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide
since December 2019, causing coronavirus disease 2019 (COVID-19). Although vaccines …
since December 2019, causing coronavirus disease 2019 (COVID-19). Although vaccines …